{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:16:56Z","timestamp":1788239816142,"version":"build-2803163510"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the predictive value of preoperative serum markers centered on human epididymis protein 4 (HE4) combined with carbohydrate antigen 125 (CA125) for the risk of suboptimal cytoreduction in advanced epithelial ovarian cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed the clinical data of 102 patients with International Federation of Gynecology and Obstetrics (FIGO) stage IIIA\u2013IV epithelial ovarian cancer who underwent primary cytoreductive surgery at the First People\u2019s Hospital of Jiangxia District between January 2021 and December 2025. Patients were divided into an optimal cytoreduction group (n=65) and a suboptimal cytoreduction group (n=37) based on the size of postoperative residual lesions. Preoperative HE4 and CA125 levels were compared between the two groups. Restricted cubic spline (RCS) functions were used to analyze dose\u2013response relationships. Multivariate Logistic regression was applied to screen independent risk factors and construct a combined prediction model. Model performance was evaluated using receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Preoperative HE4, CA125, and platelet counts were significantly higher in the suboptimal cytoreduction group than in the optimal cytoreduction group (all P&amp;lt;0.001). RCS analysis showed a linear positive correlation between marker levels and the risk of suboptimal cytoreduction. Multivariate regression revealed that each 50 pmol\/L increase in HE4 (odds ratio [OR]=1.25), each 100 U\/mL increase in CA125 (OR\u00a0=\u00a01.68), and each 10\u00d710\n                      <jats:sup>9<\/jats:sup>\n                      \/L increase in platelets (OR\u00a0=\u00a01.27) were independent risk factors (all P&amp;lt;0.05). The combined model achieved an area under the ROC curve (AUC) of 0.959 for predicting suboptimal cytoreduction, with a sensitivity of 81.1%, specificity of 95.4%, and accuracy of 90.2%, significantly outperforming single markers. Calibration curves showed good model fit (P\u00a0=\u00a00.431), and DCA demonstrated significant net clinical benefit at threshold probabilities ranging from 0.1 to 0.9.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Combined preoperative detection of serum HE4, CA125, and platelet count shows preliminary predictive potential for the risk of suboptimal cytoreduction in advanced epithelial ovarian cancer. In this single-center retrospective cohort, the three-marker combined model demonstrated promising internal predictive performance; however, its clinical applicability remains preliminary and center-specific, pending validation in independent external cohorts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1886007","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:26:51Z","timestamp":1788236811000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Preoperative serum HE4 combined with CA125 testing for predicting the risk of suboptimal cytoreduction in advanced epithelial ovarian cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Chun","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Union Jiangnan Hospital (The First People\u2019s Hospital of Jiangxia District)","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First People\u2019s Hospital of Guangshui","place":["Guangshui, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Wang","sequence":"additional","affiliation":[{"name":"Chongqing Preschool Education College","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Gezhouba Central Hospital of Sinopharm\/The Third Clinical Medical College, China Three Gorges University","place":["Yichang, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/js9.0000000000003787","article-title":"Global trends, risk factors, and future projections of ovarian cancer burden among women aged 50 years and older: a systematic analysis based on GBD 2021","volume":"112","author":"Dai","year":"2026","journal-title":"Int J Surg"},{"key":"B2","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/s12905-025-03904-y","article-title":"Analysis of global ovarian cancer disease burden and its changing trend from 1990 to 2021","volume":"25","author":"Jiang","year":"2025","journal-title":"BMC Womens Health"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e78","DOI":"10.3802\/jgo.2026.37.e78","article-title":"Comprehensive assessment of incidence, mortality, and lifetime risk of ovarian cancer: a global study with forecasts to 2050","volume":"37","author":"Jiang","year":"2026","journal-title":"J Gynecol Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15040406","article-title":"Early diagnosis of ovarian cancer: a comprehensive review of the advances, challenges, and future directions","volume":"15","author":"Hong","year":"2025","journal-title":"Diagn (Basel)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2024.108523","article-title":"The paradigm shift in advanced ovarian cancer: outcomes of extensive primary cytoreductive surgery. A single-center retrospective analysis","volume":"50","author":"Bianchi","year":"2024","journal-title":"Eur J Surg Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmig.2026.03.024","article-title":"Laparoscopic assessment of resectability in ovarian cancer: a 10-step standardized approach","author":"Chabert","year":"2026","journal-title":"J Minim Invasive Gynecol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-021-08305-x","article-title":"Evaluation of patients with advanced epithelial ovarian cancer before primary treatment: correlation between tumour burden assessed by [18F]FDG PET\/CT volumetric parameters and tumour markers HE4 and CA125","volume":"32","author":"Glickman","year":"2022","journal-title":"Eur Radiol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11061524","article-title":"Diffusion-weighted magnetic resonance imaging in ovarian cancer: exploiting strengths and understanding limitations","volume":"11","author":"Gagliardi","year":"2022","journal-title":"J Clin Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3348\/kjr.2025.0357","article-title":"CT and MRI in advanced ovarian cancer: advances in imaging techniques","volume":"26","author":"Chiu","year":"2025","journal-title":"Korean J Radiol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/life13081689","article-title":"Tumor markers and their diagnostic significance in ovarian cancer","volume":"13","author":"Matsas","year":"2023","journal-title":"Life (Basel)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-24-1845","article-title":"A prospective study consortium for the discovery and validation of early detection markers for ovarian cancer - baseline findings for CA125","volume":"31","author":"Kaaks","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2025.102682","article-title":"The utility of the novel biomarker HE4 for monitoring epithelial ovarian cancer during PARP inhibitor treatment","volume":"36","author":"Morell","year":"2026","journal-title":"Int J Gynecol Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25116265","article-title":"Diagnostic utility of selected matrix metalloproteinases (MMP-2, MMP-3, MMP-11, MMP-26), HE4, CA125 and ROMA algorithm in diagnosis of ovarian cancer","volume":"25","author":"Kicman","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"490","DOI":"10.19401\/j.cnki.1007-3639.2021.06.07","article-title":"Guidelines for the diagnosis and treatment of ovarian Malignant tumors (2021 edition)","volume":"31","year":"2021","journal-title":"Chin J Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4081\/ejtm.2022.10671","article-title":"Predicting value of HE4 and CA125 markers for optimal cytoreductive surgery in ovarian cancer patients","volume":"32","author":"Saffarieh","year":"2022","journal-title":"Eur J Transl Myol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13048-020-0614-1","article-title":"Preoperative serum levels of HE4 and CA125 predict primary optimal cytoreduction in advanced epithelial ovarian cancer: a preliminary model study","volume":"13","author":"Feng","year":"2020","journal-title":"J Ovarian Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.65342","article-title":"Evaluation of serum cancer antigen (CA)-125 levels as a biomarker for ovarian lesions: correlation with histopathological diagnosis and clinical outcomes","volume":"16","author":"Patil","year":"2024","journal-title":"Cureus"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-03165-4","article-title":"CA125 and age-based models for ovarian cancer detection in primary care: a population-based external validation study","volume":"133","author":"Arendse","year":"2025","journal-title":"Br J Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13030452","article-title":"Evaluation of He4 use in the diagnosis of ovarian cancer: first and second recurrence, and an analysis of HE4 concentration during second- and third-line chemotherapy","volume":"13","author":"Chudecka-G\u0142az","year":"2023","journal-title":"Diagn (Basel)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0314564","article-title":"The NF-\u03baB-HE4 axis: a novel regulator of HE4 secretion in ovarian cancer","volume":"19","author":"Kim","year":"2024","journal-title":"PloS One"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104465","article-title":"Unlocking the intricacies: exploring the complex interplay between platelets and ovarian cancer","volume":"202","author":"Xie","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041282","article-title":"Interactions between platelets and tumor microenvironment components in ovarian cancer and their implications for treatment and clinical outcomes","volume":"15","author":"Oncul","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119279","article-title":"Crosstalk of immune cells and platelets in an ovarian cancer microenvironment and their prognostic significance","volume":"24","author":"Pankowska","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0292282","article-title":"The role of interleukin 6 (IL6), cancer antigen-125 (CA-125), and human epididymis protein 4 (HE4) to predict tumor resectability in the advanced epithelial ovarian cancer patients","volume":"18","author":"Muhammad","year":"2023","journal-title":"PLoS One"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16213583","article-title":"Elevated platelet aggregation in patients with ovarian cancer: more than just increased platelet count","volume":"16","author":"Isingizwe","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202414129","article-title":"Molecular imaging of ovarian follicles and tumors with near-infrared II bioconjugates","volume":"37","author":"Wang","year":"2025","journal-title":"Adv Mater"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2023-0314","article-title":"A predictive and prognostic model for surgical outcome and prognosis in ovarian cancer computed by clinico-pathological and serological parameters (CA125, HE4, mesothelin)","volume":"62","author":"Klotz","year":"2024","journal-title":"Clin Chem Lab Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1421247","article-title":"Construction of a nomogram model for predicting the outcome of debulking surgery for ovarian cancer on the basis of clinical indicators","volume":"14","author":"Si","year":"2024","journal-title":"Front Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2012.11.040","article-title":"Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma","volume":"128","author":"Angioli","year":"2013","journal-title":"Gynecol Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2019-000581","article-title":"Pre-operative prediction of residual disease after interval cytoreduction for epithelial ovarian cancer using HE4","volume":"29","author":"Lof","year":"2019","journal-title":"Int J Gynecol Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1886007\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:26:53Z","timestamp":1788236813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1886007\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":30,"alternative-id":["10.3389\/fonc.2026.1886007"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1886007","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"article-number":"1886007"}}